PCSK9
Conditions
Keywords
Atrial fibrillation, Rheumatoid arthritis, PCSK9
Brief summary
Rheumatoid arthritis (RA) has been proved to increase the incidence of atrial fibrillation (AF) with persistent systemic inflammation. Proprotein convertase subtilisin/kexin type 9 (PCSK9) has been found to enhance the production of pro-inflammatory cytokines. Therefore, we performed the present study to observe the expression and significance of proprotein convertase subtilisin kexin 9 (PCSK9) in patients with RA combined atrial fibrillation.
Detailed description
Atrial fibrillation (AF), the most common clinically relevant arrhythmia, is an important contributor to population morbidity and mortality. Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease, which affects approximately 1% of the population. Increasing studies demonstrated that RA had a positive correlation with increased cardiovascular diseases. Increasing studies showed that the prevalence of AF is significantly higher in RA patients than in the general population. Recently, some studies indicated that proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes inflammatory by regulating macrophage secretion of inflammatory cytokines, inducing C-reaction protein (CRP), interleukin (IL)-6, IL-8, tumor necrosis factor-α (TNF-α) and so on. However, the levels of PCSK9 in atrial fibrillation patients with rheumatoid arthritis is still unclear. Therefore, the aim of this study was to assess the expression of PCSK9 in patients with RA combined atrial fibrillation.
Interventions
Enzyme-linked immunosorbent assay for plasma PCSK9
Sponsors
Study design
Eligibility
Inclusion criteria
1. Rheumatoid arthritis 2. Rheumatoid arthritis combined with AF
Exclusion criteria
1\. (1) History of hypertension, diabetes, cardiovascular disease, severe impairment of liver function, severe renal insufficiency. (2) Infectious diseases. (3) History malignant tumor. (4) Pregnant women, Lactating women. (5) Other autoimmune diseases. 2\. (1) History of hypertension, diabetes, cardiovascular disease (except for AF), severe impairment of liver function, severe renal insufficiency. (2) Infectious diseases. (3) History malignant tumor. (4) Pregnant women, Lactating women. (5) Other autoimmune diseases.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The expression of PCSK9 in patients with RA combined with AF | One year | To assess the expression and significance of plasma PCSK9 in three groups. |
Countries
China